4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Gene transference(Gene transference)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphoid LeukemiaSmall Lymphocytic Lymphoma

Inactive Indication-

Originator Organization

Galapagos NV

Active Organization

Galapagos NV

CellPoint BV

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Clinical Trials associated with GLPG-5201

CTIS2022-501686-47-00

/ CompletedPhase 1/2

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Start Date28 Feb 2022

Sponsor / Collaborator

Galapagos NV

100 Clinical Results associated with GLPG-5201

100 Translational Medicine associated with GLPG-5201

100 Patents (Medical) associated with GLPG-5201

117

Literatures (Medical) associated with GLPG-5201

01 Jan 2026·Case Reports in Oncological Medicine

Severe Cytokine Release Syndrome After CAR T Cell Therapy in a Pediatric Patient With Relapsed ALL

Article

Author: Alotaibi, Abdulrahman ; Alajmi, Noura ; Alnuhait, Mohammed

Background:

Cytokine release syndrome (CRS) is a potentially life‐threatening complication of chimeric antigen receptor (CAR) T cell therapy, particularly in pediatric relapsed acute lymphoblastic leukemia (ALL).

Case Presentation:

A 7‐year‐old boy with early bone‐marrow relapse of hypodiploid ALL received anti‐CD19 CAR T cells and developed severe CRS with persistent fever, hypotension, hypoxemia, encephalopathy, and multiorgan dysfunction requiring pediatric intensive care.

Management:

He received tocilizumab, high‐dose dexamethasone, continuous intravenous (IV) anakinra, and emapalumab, plus advanced supportive care (mechanical ventilation, vasopressors, and continuous renal replacement therapy). Sequential, multiagent immunomodulation was associated with transient hemodynamic stabilization.

Conclusion:

This case highlights practical bedside sequencing and escalation for refractory pediatric CRS and suggests a potential role for continuous IV anakinra and emapalumab when first‐line therapy is inadequate.

01 Dec 2025·Multiple Sclerosis and Related Disorders

CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell–driven neuroinflammation

Review

Author: Reyes-Mata, María Paulina ; Ortuño-Sahagún, Daniel ; Hermosillo-Abundis, Cristina ; Arias Carrión, Óscar

Chimeric antigen receptor (CAR) T-cell therapy is emerging as a promising approach to overcome the limitations of current B-cell-targeted treatments for multiple sclerosis (MS), particularly in progressive forms where disease-modifying therapies (DMTs) often fail to halt neuroinflammation and disability progression. By penetrating both lymphoid tissues and the central nervous system (CNS), anti-CD19 CAR T cells enable deeper and more durable depletion of autoreactive B cells than monoclonal antibodies. Preclinical studies, including experimental autoimmune encephalomyelitis (EAE) models, support their capacity to induce immune tolerance, suppress demyelinating inflammation, and modulate microglial activation. Experience from the early clinical phase -which currently includes six ongoing trials-demonstrates encouraging safety profiles, CNS trafficking of CAR T cells and evidence of pathogenic B-cell depletion in progressive MS, neuromyelitis optica spectrum disorder (NMOSD), and refractory non-relapsing phenotypes. These include the first-in-human trial CT103A (BCMA-targeted CAR T) in progressive MS and NMOSD (NCT04561557), the detection of CAR T cells in the CNS without ICANS in Anti-CD19 CAR T therapy (NCT06138132), the favorable safety in the multicenter study BMS986353 (NCT06220201), and the confirmed CNS penetration in the UCSF's KYV-101, a CD19 CAR T Cell Therapy study (NCT06451159). Next-generation CAR platforms-including regulatory CAR T cells, brain-targeted safety switches, and antigen-specific modulators-may enhance precision and mitigate neurotoxicity, a critical concern in patients with neurologically vulnerable conditions. However, key challenges remain: the absence of validated CNS-specific antigens, risks such as ICANS, delayed parkinsonian-like syndromes, or progressive multifocal leukoencephalopathy (PML), immune exhaustion within the inflamed CNS, and the logistical demands of autologous cell manufacture. This mini-review synthesizes preclinical and early clinical evidence, outlines translational barriers, and discusses strategies to optimize safety, targeting, and scalability.

01 Nov 2025·PEDIATRIC NEPHROLOGY

Anti-CD19 chimeric antigen receptor T-cell therapy in a highly sensitized patient with focal and segmental glomerulosclerosis

Article

Author: Algeri, Mattia ; Colucci, Manuela ; Del Bufalo, Francesca ; Labbadia, Raffaella ; Cappoli, Andrea ; Merli, Pietro ; Emma, Francesco ; Guzzo, Isabella ; Tomas, Nicola M ; Becilli, Marco ; Andreani, Marco ; Locatelli, Franco ; Huber, Tobias B

BACKGROUND:

High panel reactive antibody (PRA) titers are a significant challenge for patients undergoing kidney transplantation. Currently, no desensitization protocol has proven effective in preventing mid- and long-term graft loss. In the present study, we used anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in an attempt to reduce PRA in a highly sensitized patient. The role of this therapy in preventing focal segmental glomerulosclerosis (FSGS) recurrence was also evaluated.

METHODS:

An 18-year-old girl with primary kidney failure secondary to FSGS failed a first kidney transplant at age 4 years due to disease recurrence. Despite being listed in a special program for hyperimmune patients, she had not been offered a new kidney. She received a single infusion of anti-CD19 CAR T cells after lymphodepletion therapy. Anti-human leukocyte antigens (HLA) antibody titers were monitored before therapy and monthly thereafter.

RESULTS:

PRA titers decreased progressively during the first 6 months after CAR T-cell therapy. Unexpectedly, after 5.5 months, the patient was offered a cadaveric kidney that was fully matched for HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ at the antigen level. However, she developed an early relapse of FSGS for which she started plasmapheresis, which prevented further monitoring of PRA titers.

CONCLUSIONS:

This case shows that a single infusion of anti-CD19 CAR T cells can induce a durable reduction of anti-HLA antibodies in highly sensitized patients. However, profound B-cell depletion did not prevent FSGS relapse.

News (Medical) associated with GLPG-5201

26 Feb 2025

·www.biospace.com

How To Mine Biopharma’s IP Storeroom for Rare Disease Drugs, Just Like SpringWorks

iStock, cyano66 SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for every rare disease, experts say. The biopharma industry has never been better at making drug candidates than it is in this moment. But not everything that comes out of the drug discovery engine will get developed, even if curative. It’s hard to comprehend the scope of the drugs, research and intellectual property sitting on pharma shelves, or being lost as biotechs shut down. Annette Bakker, CEO of the Children’s Tumor Foundation (CTF) that supported the development of SpringWorks Therapeutics’ newly approved rare disease drug Gomekli, estimates that there are probably 30 more drugs out there right now that could help patients with neurofibromatosis if they weren’t in limbo. “This is one drug, but it’s definitely not the last one,” Bakker said. “And what we actually really hope is that this may trigger a motivation for some other companies.” Gomekli’s journey from Pfizer’s storeroom to approval is a perfect case study that Bakker and SpringWorks Chief Medical Officer Jim Cassidy say could be replicated over and over. “What we’re building now can actually be copied to every rare disease under the sun,” Bakker said. Gomekli is now estimated to bring in about $760 million by 2030, according to Bakker, so the opportunity is real for companies willing to wade into the dust and cobwebs of pharma’s attic. “There is just a whole energy here that I think is worth exploring now that we have a success, Bakker said. “How can we make this a sustainable endeavor going forward? Because for [Gomekli], this . . . was a fantastic experience, but now we need to think about making this a scalable opportunity.” The Ghosts of Biotechs Past Smaller biotechs also churn out assets that never see the light of the day. Carl Schoellhammer, associate partner at consulting firm DeciBio, calls these “ghost assets.” Myriad reasons can drive a biotech out of business, but it’s not always because a drug failed. A company may simply be unable to secure a new round of fundraising. This leaves them attempting a fire sale of the assets, or they simply fade away and the science is never seen again, Schoellhammer explained. The issue is particularly prominent among platform companies, which were all the rage a few years ago but have petered out as the industry turned to focus on single assets with data behind them. Bakker thinks the problem is getting worse. “You see that a lot of companies are restructuring these days, and I think we’re going to have even a more pronounced wave of what I call shell drugs that actually will never see the patient. And for a rare disease, that is a problem.” Schoellhammer predicts that areas like mRNA or cell therapy are likely to create these poltergeists in the years to come. Companies that launched in the heyday of COVID to advance mRNA have not really figured out the next phase of this technology. Even Moderna, the most famous name in the mRNA game, is struggling to find the right indications for its tech. For cell therapy, Schoellhammer predicts that CD19 CAR T programs will likely be cast off in the years to come. Several of these therapies have already been approved, leaving dozens still in development. Galapagos just deprioritized CD19 CAR T candidate GLPG5201 after years of development, he noted. For a lot of smaller cell therapy companies, they raised funds when the industry was at a high. “Everyone thought that cell therapies are gonna be the end all be all,” Schoellhammer said. “There’s some question marks [now], and they couldn’t raise again.” Galapagos is well capitalized with about €500 million ($525.8 million) in the bank to last into 2028 and can afford to move onto the next candidate in line, in this case GLPG5101. A smaller company cannot. When facing this problem, biotechs can try and sell the assets off. If they can’t find a buyer, they could pay to maintain the IP, but that’s a huge expense that a failing biotech probably does not have the cash to cover. A venture capital firm that had backed the company is unlikely to want the hassle of trying to form a new company around an old asset, Schoellhammer said. If the IP came from a research organization, it can be transferred back there. But often the assets drift off never to be seen again. According to Bakker, drugs from small biotechs can get lost in an acquisition focused on another drug. If the smaller company had filed an investigational new drug application for another asset with the FDA prior to being acquired, no one can access those data because the smaller company no longer exists after it’s absorbed into a bigger one. The data are simply lost. “That, I think, is a huge problem for the patients, but also it’s pretty unethical that we would have to do these toxicology studies on cats and dogs because we can’t access that data,” Bakker said. Policy solutions could help incentivize development of shelves assets, too. Bakker suggested tax incentives for companies and that the FDA loosen its policies on old IND filings to ensure that data are not lost if a company goes away. According to Cassidy, the key for getting Gomekli across the FDA’s finish line was CTF. And if you ask Bakker, it was having a company like Pfizer that was willing to spin out the intellectual property, and then the volunteers to make it happen. Cassidy said SpringWorks was very lucky that Pfizer was willing, but that’s not always the case. “It’s all very well making a fuss over a drug that’s been discontinued. . . . Most drug companies, they’ll be deaf to that from the outside world. You have to be really persistent, really tenacious and really go for the right people in the company . . . and influence them in the right way,” Cassidy said. “We can’t do that. That’s got to be a CTF-like organization.” Investors also need to be identified who would be willing to take a chance and form new entities around these orphaned assets. Bakker also thinks that biotech accelerators could focus on them. “What I’m working on now is creating almost like an investor club of people that are willing to sustain these companies to make sure that they make it to the finish line,” Bakker said. Both Cassidy and Schoellhammer said that another strategy to capturing dismissed assets is via a holding company, which would pick up assets being sold off as companies shut down and assemble the resources to advance them. Now that Gomekli is approved, Bakker is eager to share her expertise and move on to the next potential asset. She is working with the FDA, Sanofi and the Myhre Syndrome Foundation to see if rare diseases can be clustered together by type to broaden the treatment opportunities. CTF is also developing an infrastructure to help public and private institutions collaborate to develop drugs efficiently and a clinical trials consortium to facilitate the movement of drugs into the clinic. “Our approach is, let us build a prototype that actually can be expanded to other rare disease,” Bakker said. “So it’s not just for NF.” Editor’s note: The following story is part one in a two part story looking at discontinued assets in biopharma. You can read Part One, How SpringWorks Took Pfizer’s Rare Disease Ghost Drug And Got it to Patients , here .

Cell Therapy

13 Feb 2025

·www.fiercebiotech.com

Galapagos drops one CD19 CAR-T to focus on \'flagship\' program

Galapagos CEO Paul Stoffels, M.D., pointed to “compelling” phase 1/2 data from GLPG5101 in three types of lymphoma.\n Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate the business.The company had been planned to secure permission from the FDA in “early 2025” to launch a phase 1/2 study of the therapy, dubbed GLPG5201, in relapsed/refractory chronic lymphocytic (CLL) leukemia and Richter transformation (RT). Galapagos had already obtained the nod from the European Medicines Agency for a phase 2 dose expansion study of GLPG5201 in the same patient population, with enrollment penciled in for this year.But the biotech is now deprioritizing the therapy, Galapagos revealed in its fourth-quarter earnings release.The decision was made with the goal of “streamlining” the business, said Galapagos, which wants to focus its resources on its “flagship” CD19 CAR-T program, GLPG5101.In the release, Galapagos CEO Paul Stoffels, M.D., pointed to “compelling” phase 1/2 data from GLPG5101 in three types of lymphoma that had been presented at the American Society of Hematology annual meeting in December. The findings included an objective response rate of 69% among 13 evaluable patients with diffuse large B-cell lymphoma. That study is ongoing in Europe, and Galapagos has recently secured FDA permission to expand the trial to the U.S. The range of indications being assessed will also stretch to include CLL and RT.“In line with our goal of becoming a more focused and streamlined organization, we are optimizing our CD19 CAR-T portfolio by prioritizing resources where they can have the greatest impact,” Stoffels said in the Feb. 13 postmarket release.“We are expanding the development of GLPG5101, our most advanced asset by extending its reach into additional aggressive B-cell malignancies, including Richter transformation of CLL, and are taking action to expand into double-refractory CLL,” the CEO added. “We are deprioritizing activities related to GLPG5201, our second CD19 CAR-T candidate, pending the advancement of GLPG5101 in those additional indications.”The planned split-up of Galapagos, which the company announced last month, remains on track, according to yesterday’s release. The move will leave one company with the Galapagos name and its portfolio of cell therapies, while the other, as yet unnamed, entity will “focus on building a pipeline of innovative medicines through transformational transactions,” the biotech explained at the time.

$Galapagos drops one CD19 CAR-T to focus on \'flagship\' program$

Phase 2Cell TherapyASH

30 Oct 2024

·www.globenewswire.com

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance of the Investigational New Drug (IND) application for the Phase 1/2 ATALANTA-1 study of our CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL), marking an important step forward in our cell therapy pipeline using our innovative decentralized manufacturing platform.We resumed recruitment in the Phase 1/2 PAPILIO-1 study with our BCMA CAR-T candidate, GLPG5301, in relapsed/refractory multiple myeloma (R/R MM). As part of our collaboration agreement with Blood Centers of America (BCA), we selected Excellos in the San Diego area as the first decentralized manufacturing unit (DMU) within BCA’s nationwide network to manufacture GLPG5101 for the ATALANTA-1 study sites in the region. We further advanced our early-stage proprietary pipeline and progressed a next-generation armed, bispecific CAR-T candidate in hemato-oncology and a potential best-in-class small molecule candidate in immunology into IND-enabling studies, targeting clinical development in 2025-2026.We have €3.3 billion in cash and financial investments as of September 30, 2024, supporting our pipeline. We reconfirm the full-year 2024 cash burni guidance of €370 million to €410 million. Webcast presentation on October 31, 2024, at 13:00 CET / 8:00 am ET, www.glpg.com Mechelen, Belgium; October 30, 2024, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced financial results for the first nine months of 2024 and provided a business update. “I am proud of our team’s commitment in executing our Forward, Faster strategy,” said Paul Stoffels1, MD, Galapagos’ CEO and Chair of the Board of Directors. “The FDA's clearance of the ATALANTA-1 study of GLPG5101, produced on our decentralized manufacturing platform in patients with relapsed/refractory non-Hodgkin lymphoma, marks a pivotal step towards realizing our vision of transforming patient outcomes through life-changing science and innovation. This is the first-ever FDA clearance for a clinical study in the U.S. with a fresh CAR-T product candidate delivered in a median vein-to-vein time of seven days. We remain focused on advancing our clinical pipeline in 11 indications and our potential best-in-class early-stage programs across multiple modalities and indications.” “With more than 20 active cell therapy and small molecule programs in oncology and immunology, we are accelerating our internal pipeline while we continue to assess business development opportunities. We reaffirm our 2024 cash burn guidance in the range of €370-410 million,” Thad Huston, Galapagos’ CFO and COO, added. Third quarter and recent business highlights and anticipated milestonesRegulatory and pipeline: The investigational new drug (IND) application for the Phase 1/2 ATALANTA-1 study of our CD19 candidate, GLPG5101, in R/R NHL has been cleared by the U.S. Food and Drug Administration (FDA) and our goal is to activate clinical study sites and start enrolling patients in the U.S. before the end of 2024.We expect to submit an IND in early 2025 for the Phase 1/2 EUPLAGIA-1 study in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and Richter transformation (RT) of our CD19 CAR-T candidate, GLPG5201.Following the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the Phase 2 dose expansion study of GLPG5201 in R/R CLL and RT, we aim to start enrolling patients in 2025.We resumed enrolment in the Phase 1/2 PAPILIO-1 study of our BCMA CAR-T candidate, GLPG5301, in R/R MM.We will present new data from the ATALANTA-1 and EUPLAGIA-1 studies along with pre-clinical data for uza-cel, our TCR-T cell therapy candidate produced on our decentralized manufacturing platform in collaboration with Adaptimmune, at the American Society of Hematology (ASH) Annual Meeting in December.We continued enrolling patients in the ongoing Phase 2 GALARISSO study in dermatomyositis (DM) and the Phase 2 GALACELA study in systemic lupus erythematosus (SLE) with our oral small molecule TYK2 inhibitor, GLPG3667.We further advanced our early-stage proprietary pipeline and progressed a next-generation armed, bispecific CAR-T candidate in hemato-oncology and a potential best-in-class small molecule candidate in immunology into IND-enabling studies, targeting clinical development in 2025-2026.We are accelerating our early-stage pipeline of more than 15 programs in oncology and immunology with the objective of launching at least four IND/CTA-enabling studies in 2025 across different modalities and indications. From 2026 onward, our ambition is to fuel the clinical pipeline with at least two new clinical assets annually in various indications and across our cell therapy and small molecule portfolio. Operational: As part of our collaboration agreement with Blood Centers of America (BCA), we selected Excellos in the San Diego area as the first decentralized manufacturing unit (DMU) within BCA’s nationwide network to manufacture GLPG5101 for the ATALANTA-1 study sites in the region.We continue to expand our DMU network in Europe and the U.S. to manufacture our cell therapy candidates for clinical development and to support pivotal and commercial readiness. External innovation: We are exploring strategic partnerships, early-stage research collaborations, licensing, and bolt-on acquisitions in areas of high unmet medical need to accelerate our cell therapy and small molecule pipeline in oncology and immunology. Corporate: The Board of Directors appointed Mr. Oleg Nodelman as Non-Executive Non-Independent Director by way of co-optation effective October 7, 2024, replacing Dr. Dan Baker who stepped down on October 6, 2024. Financial performanceKey figures for the first nine months of 2024 (consolidated)(€ millions, except basic & diluted earnings per share) Nine months ended September 30 % Change 2024 2023 Supply revenues 19.1 - Collaboration revenues 181.0 179.8 +1% Total net revenues 200.1 179.8 +11% Cost of sales (19.1) - R&D expenses (238.2) (167.2) +42% G&Aii and S&Miii expenses (93.2) (87.4) +7% Other operating income 24.8 32.9 -25% Operating loss (125.6) (41.9) Fair value adjustments and net exchange differences 31.8 36.3 -12% Net other financial result 71.7 54.0 +33% Income taxes 1.7 (12.2) Net profit/loss (-) from continuing operations (20.4) 36.2 Net profit from discontinued operations, net of tax 69.2 17.9 Net profit of the period 48.8 54.1 Basic and diluted earnings per share (€) 0.7 0.8 Current financial investments, cash & cash equivalents 3,338.8 3,811.7 DETAILS OF THE FINANCIAL RESULTS FOR THE FIRST NINE MONTHS OF 2024As a consequence of the transfer of our Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the first nine months of 2024 are presented separately from the results of our continuing operations in the line ‘Net profit from discontinued operations, net of tax’ in our consolidated income statement. The comparative first nine months of 2023 have been restated accordingly for the presentation of the results related to the Jyseleca® business. Results from our continuing operationsTotal operating loss from continuing operations for the nine months ended September 30, 2024, was €125.6 million, compared to an operating loss of €41.9 million for the nine months ended September 30, 2023. Total net revenues for the nine months ended September 30, 2024, amounted to €200.1 million, compared to €179.8 million for the nine months ended September 30, 2023. The revenue recognition related to the exclusive access rights granted to Gilead for our drug discovery platform amounted to €172.7 million for the first nine months of both 2024 and 2023. Our deferred income balance on September 30, 2024, includes €1.1 billion allocated to our drug discovery platform that is recognized linearly over the remaining period of our 10-year collaboration. Cost of sales for the nine months ended September 30, 2024, amounted to €19.1 million and related to the supply of Jyseleca® to Alfasigma under the transition agreement. The related revenues are reported in total net revenues.R&D expenses in the first nine months of 2024 amounted to €238.2 million, compared to €167.2 million for the first nine months of 2023. This increase was primarily explained by higher costs for cell therapy and small molecule programs in oncology.G&A and S&M expenses amounted to €93.2 million in the first nine months of 2024, compared to €87.4 million in the first nine months of 2023. This increase was primarily due to an increase in legal and professional fees, mainly related to business development activities and due to an increase in S&M expenses due to investments in strategic marketing for oncology. Both increases were partly offset by a decrease in G&A personnel expenses, mainly due to a decreased cost for our subscription rights plans.Other operating income amounted to €24.8 million in the first nine months of 2024, compared to €32.9 million for the same period last year. This decrease is mainly driven by lower grants and R&D incentives. Net financial income in the first nine months of 2024 amounted to €103.5 million, compared to net financial income of €90.3 million for the first nine months of 2023. Fair value adjustments and net currency exchange results in the first nine months of 2024 amounted to €31.8 million, compared to fair value adjustments and net currency exchange gains of €36.3 million for the first nine months of 2023, and were primarily attributable to €3.1 million of unrealized currency exchange losses on our cash and cash equivalents and current financial investments at amortized cost in U.S. dollars, and to €35.7 million of positive changes in fair value of current financial investments.Net other financial income in the first nine months of 2024 amounted to €71.7 million, compared to net other financial income of €54.0 million for the first nine months of 2023, and was primarily attributable to €70.6 million of interest income, which increased significantly due to the increase in interest rates. Net tax income in the first nine months of 2024 amounted to €1.7 million, compared to net tax expenses of €12.2 million for the first nine months of 2023. The net tax expenses in 2023 were primarily due to the re-assessment of net deferred tax liabilities and corporate income tax payables as a result of a one-off intercompany transaction. Net loss from continuing operations for the first nine months of 2024 was €20.4 million, compared to a net profit from continuing operations of €36.2 million for the first nine months of 2023.Results from discontinued operations (€ millions) Nine months ended September 30 % Change 2024 2023 Product net sales 11.4 82.1 -86% Collaboration revenues 26.0 187.0 -86% Total net revenues 37.4 269.1 -86% Cost of sales (2.2) (13.5) -84% R&D expenses (13.6) (145.0) -91% G&A and S&M expenses (10.8) (94.7) -89% Other operating income 55.2 7.1 Operating profit 66.0 23.0 Net financial result 3.3 (3.7) Income taxes (0.1) (1.4) Net profit from discontinued operations 69.2 17.9 Total operating profit from discontinued operations amounted to €66.0 million in the first nine months of 2024, compared to an operating profit of €23.0 million in the same period last year. Product net sales of Jyseleca® in Europe were €11.4 million for the first nine months of 2024 consisting of sales to customers in January 2024. Product net sales to customers for the first nine months of 2023 amounted to €82.1 million. As from February 1, 2024, all economics linked to the sales of Jyseleca® in Europe are to the benefit of Alfasigma.Collaboration revenues for the development of filgotinib with Gilead amounted to €26.0 million for the first nine months of 2024, compared to €187.0 million for the same period last year. The sale of the Jyseleca® business to Alfasigma on January 31, 2024, led to the full recognition in revenue of the remaining deferred income related to filgotinib. Cost of sales related to Jyseleca® net sales were €2.2 million for the first nine months of 2024. Cost of sales related to Jyseleca® net sales for the first nine months of 2023 amounted to €13.5 million. R&D expenses for the development of filgotinib for the first nine months of 2024 amounted to €13.6 million, compared to €145.0 million in the first nine months of 2023. As from February 1, 2024, all filgotinib development expenses still incurred during the transition period are recharged to Alfasigma.G&A and S&M expenses related to the Jyseleca® business amounted to €10.8 million in the first nine months of 2024, compared to €94.7 million in the first nine months of 2023. As from February 1, 2024, all remaining G&A and S&M expenses relating to Jyseleca® are recharged to Alfasigma.Other operating income for the first nine months of 2024 amounted to €55.2 million (€7.1 million for the same period last year) and comprised €52.3 million related to the gain on the sale of the Jyseleca® business to Alfasigma. This result as of September 30, 2024, of the transaction is considering the following elements: €50.0 million of upfront payment received at closing of the transaction of which €40.0 million was paid on an escrow account. This amount will be kept in escrow for a period of one year after the closing date of January 31, 2024. We gave customary representations and warranties which are capped and limited in time (at September 30, 2024, this €40.0 million is presented as “Escrow account” in our statement of financial position).€9.8 million of cash received from Alfasigma related to the closing the transaction as well as €0.9 million of accrued negative adjustment for the settlement of net cash and working capital.€47.0 million of fair value on January 31, 2024, of the future earn-outs payable by Alfasigma to us (the fair value of these future earn-outs at September 30, 2024, is presented on the lines “Non-current contingent consideration receivable” and “Trade and other receivables”). As from February 1, 2024, we are entitled to receive royalties on net sales of Jyseleca® in Europe from Alfasigma.€40.0 million of liability towards Alfasigma on January 31, 2024, for R&D cost contributions of which €15.0 million was paid in the first nine months of 2024 (at September 30, 2024, €25.0 million of liabilities for R&D cost contribution is presented in our statement of financial position on the line “Trade and other liabilities”). Net profit from discontinued operations related to Jyseleca® amounted to €69.2 million for the first nine months of 2024, compared to a net profit amounting to €17.9 million for the first nine months of 2023. Cash, cash equivalents and current financial investments totaled €3,338.8 million as of September 30, 2024, as compared to €3,684.5 million as of December 31, 2023. Total net decrease in cash and cash equivalents and current financial investments amounted to €345.7 million during the first nine months of 2024, compared to a net decrease of €282.4 million during the first nine months of 2023. This net decrease was composed of (i) €321.3 million of operational cash burn including €80.4 million cash impact of business development activities, (ii) €36.9 million for the acquisition of financial assets held at fair value through other comprehensive income, (iii) €26.2 million of net cash in related to the sale of the Jyseleca® business to Alfasigma of which €40.0 million has been transferred to an escrow account, offset by (iv) €26.3 million of negative exchange rate differences, positive changes in fair value of current financial investments and variation in accrued interest income. Financial guidanceAs of September 30, 2024, we have €3.3 billion in cash and current financial investments to continue to fund our proprietary pipeline and pursue select, value-enhancing deals. We reiterate our cash burn guidance, including business development year-to-date, for the full year 2024, which is expected to be in the range of €370 million to €410 million. Conference call and webcast presentationWe will host a conference call and webcast presentation on October 31, 2024, at 13:00 CET / 8:00 am ET. To participate in the conference call, please register in advance using this link. Dial-in numbers will be provided upon registration. The conference call can be accessed 10 minutes prior to the start of the call by using the conference access information provided in the email received after registration, or by selecting the “call me” feature. The live webcast is available on glpg.com or via the following link. The archived webcast will be available for replay shortly after the close of the call on the investor section of the website. Expected financial calendar 2025 February 12, 2025March 27, 2025April 23, 2025April 29, 2025July 23, 2025October 22, 2025 Full year 2024 resultsAnnual report 2024First quarter 2025 resultsAnnual Shareholders’ MeetingHalf-year 2025 resultsThird quarter 2025 results (webcast: February 13, 2025) (webcast: April 24, 2025) (webcast: July 24, 2025)(webcast: October 23, 2025) About Galapagos’ Forward, Faster Strategy Our Forward, Faster strategy is focused on accelerating growth and value creation by reimagining how we innovate and operate, driven by our purpose to transform patient outcomes for more years of life and quality of life across the globe. This strategy focuses on three pillars: Patient-centric research and development to address medical needs in our key therapeutic areas of oncology and immunology.Build on our current capabilities and de-risking R&D through multiple drug modalities, including cell therapy, and by focusing on best-in-class validated targets with shorter time-to-patient potential.Expanding business development efforts to complement our pipeline, continuing to work with our collaboration partner Gilead, to bring transformational medicines to the broadest patient population possible. About GalapagosWe are a biotechnology company with operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, and the financial strength to invest strategically for the near- and long-term, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For additional information, please visit www.glpg.com or follow us on LinkedIn or X. For further information, please contact: Media inquiries:Srikant Ramaswami+1 412 699 0359 Marieke Vermeersch +32 479 490 603 Jennifer Wilson + 44 7539 359 676 media@glpg.com Investor inquiries:Sofie Van Gijsel +1 781 296 1143Sandra Cauwenberghs +32 495 58 46 63ir@glpg.com Forward-looking statementsThis press release contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “plan,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “advance,” “ambition,” “outlook,” “further,” as well as similar expressions. These statements include, but are not limited to, the guidance from management regarding our financial results (including guidance regarding the expected operational use of cash for the fiscal year 2024), statements regarding our regulatory outlook, statements regarding the amount and timing of potential future milestones, including potential milestone payments, statements regarding our R&D plans, strategy and outlook, including progress on our oncology or immunology portfolio, and our CAR-T-portfolio, and potential changes of such plans, statements regarding our pipeline and complementary technology platforms facilitating future growth, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials, including but not limited to (i) GLPG3667 in SLE and DM, (ii) GLPG5101 in R/R NHL, (iii) GLPG5201 in R/R CLL and RT, and (iv) GLPG5301 in R/R MM, statements regarding the potential attributes and benefits of our product candidates, statements regarding our commercialization efforts for our product candidates and any of our future approved products, if any, statements about potential future commercial manufacturing of T-cell therapies, statements related to the IND application for the Phase 1/2 ATALANTA-1 study, statements related to the anticipated timing for submissions to regulatory agencies, including any INDs or CTAs, statements relating to the development of our distributed manufacturing capabilities on a global basis, and statements related to our portfolio goals and business plans. Galapagos cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause our actual results, financial conditions and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, the risk that our expectations and management’s guidance regarding our 2024 operating expenses, cash burn and other financial estimates may be incorrect (including because one or more of our assumptions underlying our revenue and expense expectations may not be realized), the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all, the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements (including the risk that data from our ongoing and planned clinical research programs in DM, SLE, R/R NHL, R/R CLL, RT, R/R MM and other immunologic and oncologic indications or any other indications or diseases, may not support registration or further development of our product candidates due to safety or efficacy concerns or other reasons), the risk that we may not be able to realize the expected benefits from the appointment (by way of co-optation) of the new Director, the risk that the preliminary and topline data from our studies, including the ATALANTA-1, EUPLAGIA-1 and PAPILIO-1-studies, may not be reflective of the final data, risks related to our reliance on collaborations with third parties (including, but not limited to, our collaboration partners Gilead, Lonza, Adaptimmune, BridGene Biosciences and Blood Centers of America), the risk that the transfer of the Jyseleca® business will not have the currently expected results for our business and results of operations, the risk that our plans with respect to our CAR-T programs may not be achieved on the currently anticipated timeline or at all, the risk that our estimates of the commercial potential of our product candidates (if approved) or expectations regarding the costs and revenues associated with any commercialization rights may be inaccurate, the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will revise our business plan, and risks related to our strategic transformation, including the risk that we may not achieve the anticipated benefits of such exercise on the currently envisaged timeline or at all. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports filed with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation. Addendum Consolidated statements of income and comprehensive income/loss (-) (unaudited) Consolidated income statement Nine months endedSeptember 30 (thousands of €, except per share data) 2024 2023 Supply revenues 19,124 - Collaboration revenues 181,030 179,784 Total net revenues 200,154 179,784 Cost of sales (19,124) - Research and development expenses (238,270) (167,211) Sales and marketing expenses (10,177) (3,884) General and administrative expenses (83,013) (83,556) Other operating income 24,813 32,950 Operating loss (125,617) (41,916) Fair value adjustments and net currency exchange differences 31,762 36,251 Other financial income 72,553 55,096 Other financial expenses (814) (1,056) Profit/loss (-) before tax (22,116) 48,375 Income taxes 1,710 (12,158) Net profit/loss (-) from continuing operations (20,406) 36,217 Net profit from discontinued operations, net of tax 69,181 17,921 Net profit 48,775 54,138 Net profit attributable to: Owners of the parent 48,775 54,138 Basic and diluted earnings per share 0.74 0.82 Basic and diluted earnings/loss (-) per share from continuing operations (0.31) 0.55 Consolidated statement of comprehensive income/loss (–) Nine months endedSeptember 30 (thousands of €) 2024 2023 Net profit 48,775 54,138 Items that will not be reclassified subsequently to profit or loss: Re-measurement of defined benefit obligation 74 - Fair value adjustment financial assets held at fair value through other comprehensive income (1,329) - Items that may be reclassified subsequently to profit or loss: Translation differences, arisen from translating foreign activities 338 318 Realization of translation differences upon sale of foreign operations 4,095 - Other comprehensive income, net of income tax 3,178 318 Total comprehensive income attributable to: Owners of the parent 51,953 54,456 Total comprehensive income attributable to owners of the parent arises from: Continuing operations (21,587) 36,731 Discontinued operations 73,540 17,725 Total comprehensive income, net of income tax 51,953 54,456 Consolidated statement of financial position (unaudited) (thousands of €) September 30, 2024 December 31, 2023 Assets Goodwill 69,465 69,557 Intangible assets other than goodwill 173,431 127,906 Property, plant and equipment 132,234 126,321 Deferred tax assets 1,153 1,126 Non-current R&D incentives receivables 133,401 141,252 Non-current contingent consideration receivable 42,726 - Equity investments 49,125 13,575 Other non-current assets 11,239 16,069 Non-current assets 612,774 495,807 Inventories 65,563 73,978 Trade and other receivables 45,426 28,449 Current R&D incentives receivables 41,801 37,436 Current financial investments 3,283,256 3,517,698 Cash and cash equivalents 55,523 166,803 Escrow account 40,880 - Other current assets 26,979 15,140 Current assets from continuing operations 3,559,428 3,839,504 Assets in disposal group classified as held for sale - 22,085 Total current assets 3,559,428 3,861,589 Total assets 4,172,202 4,357,396 Equity and liabilities Share capital 293,937 293,937 Share premium account 2,736,994 2,736,994 Other reserves (7,041) (5,890) Translation differences 3,128 (1,201) Accumulated losses (164,448) (228,274) Total equity 2,862,570 2,795,566 Retirement benefit liabilities 2,291 2,293 Deferred tax liabilities 20,966 23,607 Non-current lease liabilities 7,240 4,944 Other non-current liabilities 30,904 31,570 Non-current deferred income 896,999 1,071,193 Non-current liabilities 958,400 1,133,607 Current lease liabilities 4,225 4,652 Trade and other liabilities 115,858 135,201 Current tax payable 216 56 Current deferred income 230,933 256,270 Current liabilities from continuing operations 351,232 396,179 Liabilities directly associated with assets in disposal group classified as held for sale - 32,044 Total current liabilities 351,232 428,223 Total liabilities 1,309,632 1,561,830 Total equity and liabilities 4,172,202 4,357,396 Consolidated cash flow statements (unaudited) Nine months endedSeptember 30 (thousands of €) 2024 2023 Net profit of the period 48,775 54,138 Adjustment for non-cash transactions 24,291 44,344 Adjustment for items to disclose separately under operating cash flow (71,525) (40,165) Adjustment for items to disclose under investing and financing cash flows (68,206) (11,809) Change in working capital other than deferred income (50,804) (50,329) Cash used for other liabilities related to the sale of subsidiaries (3,598) - Decrease in deferred income (198,927) (359,259) Cash used in operations (319,994) (363,081) Interest paid (592) (3,729) Interest received 60,523 35,063 Corporate taxes paid (594) (7,357) Net cash flows used in operating activities (260,657) (339,104) Purchase of property, plant and equipment (11,300) (11,073) Purchase of and expenditure in intangible fixed assets (65,110) (222) Proceeds from disposal of property, plant and equipment - 2,304 Purchase of current financial investments (2,021,246) (2,615,112) Investment income received related to current financial investments 15,511 9,857 Sale of current financial investments 2,281,471 2,609,023 Cash out from sale of subsidiaries, net of cash disposed (10,209) - Acquisition of financial assets held at fair value through other comprehensive income (36,880) - Net cash flows generated from/used in (-) investing activities 152,237 (5,222) Payment of lease liabilities (3,320) (5,580) Proceeds from capital and share premium increases from exercise of subscription rights - 1,770 Net cash flows used in financing activities (3,320) (3,810) Decrease in cash and cash equivalents (111,740) (348,136) Cash and cash equivalents at beginning of the year 166,810 508,117 Decrease in cash and cash equivalents (111,740) (348,136) Effect of exchange rate differences on cash and cash equivalents 453 (607) Cash and cash equivalents at end of the period 55,523 159,375 Consolidated statements of changes in equity (unaudited) (thousands of €) Share capital Share premium account Translation differences Other reserves Accumulated losses Total On January 1, 2023 293,604 2,735,557 (1,593) (4,853) (496,689) 2,526,026 Net profit 54,138 54,138 Other comprehensive income/loss (-) 397 (79) 318 Total comprehensive income/loss (-) 397 (79) 54,138 54,456 Share-based compensation 39,308 39,308 Exercise of subscription rights 333 1,437 1,770 On September 30, 2023 293,937 2,736,994 (1,196) (4,932) (403,242) 2,621,560 On January 1, 2024 293,937 2,736,994 (1,201) (5,890) (228,274) 2,795,566 Net profit 48,775 48,775 Other comprehensive income/loss (-) 4,329 (1,151) 3,178 Total comprehensive income/loss (-) 4,329 (1,151) 48,775 51,953 Share-based compensation 15,051 15,051 On September 30, 2024 293,937 2,736,994 3,128 (7,041) (164,448) 2,862,570 1 Throughout this press release, ‘Dr. Paul Stoffels’ should be read as ‘Dr. Paul Stoffels, acting via Stoffels IMC BV’. i The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:• the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities• the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in current financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities• the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.This alternative liquidity measure is in our view an important metric for a biotech company in the development stage. The operational cash burn for the first nine months of 2024 amounted to €321.3 million and can be reconciled to our cash flow statement by considering the decrease in cash and cash equivalents of €111.8 million, adjusted by (i) the net sale of current financial investments amounting to €260.2 million, (ii) the cash-out related to the sale of subsidiaries of €13.8 million, and (iii) the acquisition of financial assets held at fair value through other comprehensive income of €36.9 million.ii General and administrativeiii Sales and marketing Attachment Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Phase 2Executive ChangeASHCell TherapyFinancial Statement

100 Deals associated with GLPG-5201

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Chronic Lymphoid Leukemia	Phase 2	Belgium	Galapagos NV	28 Feb 2022
Recurrent Chronic Lymphoid Leukemia	Phase 2	Netherlands	Galapagos NV	28 Feb 2022
Recurrent Chronic Lymphoid Leukemia	Phase 2	Spain	Galapagos NV	28 Feb 2022
Small Lymphocytic Lymphoma	Phase 2	Spain	Galapagos NV	21 Feb 2022
Chronic Lymphocytic Leukemia	Phase 2	Spain	CellPoint BV	21 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Recurrent Chronic Lymphoid Leukemia	-	GLPG5201 DL1	mqnqfseztc(xuunhhumdq) = No Grade ≥3 CRS or any-grade ICANS were observed; CRS Grade 1-2 occurred in 8 (53%) pts mcgelzvovr (fjqcyesdvv ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Recurrent Chronic Lymphoid Leukemia	-	GLPG5201 DL2		-	08 Dec 2024
EUCTR2021-003272-13-BE (ATALANTA-1, GlobeNewswire) Manual	Phase 1/2	Non-Hodgkin Lymphoma CD19 Positive	14	GLPG5101 (Phase 1)	ycyduhuyks(eopqzsjofc) = kdrehbgpcy fbryegkpue (alkotzadpr ) View more	Positive	09 Dec 2023
EUCTR2021-003815-25-ES (EUPLAGIA-1, GlobeNewswire) Manual	Phase 1	Chronic Lymphocytic Leukemia CD19	14	GLPG5201	ysiakmzxyl(zqftcuurum) = most treatment emergent adverse events (TEAEs) of Grade 1 or 2, mostly hematological. bvdptzusoc (lktezwagla ) View more	Positive	09 Dec 2023
EUCTR2021-003815-25-ES (Euplagia-1, ASH2023) Manual	Phase 1/2	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	12	GLPG5201 35×10^6	ebeimvtdiq(babitfwwky) = Most treatment emergent adverse events were Grade 1–2; most Grade ≥3 events were hematological. Six (50%) pts had Grade 1–2 cytokine release syndrome (CRS), with no CRS Grade ≥3. No neurotoxicity was reported. ffeismxzmk (dmxlnangfk )	Positive	09 Dec 2023
EUCTR2021-003815-25-ES (Euplagia-1, ASH2023) Manual	Phase 1/2	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	12	GLPG5201 100×10^6		Positive	09 Dec 2023
EUCTR2021-003815-25-ES (Euplagia-1/CP0101-CLL, EHA2023)	Phase 1/2	Recurrent Chronic Lymphoid Leukemia \| Chronic lymphocytic leukaemia refractory \| Refractory Small Lymphocytic Lymphoma	7	GLPG5201	btfvbpccol(pydxkvbknq) = lalpdrbbiq gusvwgfaet (lerkdizztf ) View more	-	08 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis